Cancer-related inflammation
Open accessThe DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.
Abstract
The mediators and cellular effectors of inflammation are important constituents of the local environment of tumours. In some types of cancer, inflammatory conditions are present before a malignant change occurs. Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours. Regardless of its origin, 'smouldering' inflammation in the tumour microenvironment has many tumour-promoting effects. It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents. The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, cytokine production can be triggered by oncogenic transformation, metabolic alteration, cell death, hypoxia, and the use of anti-cancer drugs (10).”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Excessive or dysregulated inflammation is a major driver of tissue damage and the pathogenesis of numerous diseases, including stroke, Parkinson’s disease, atherosclerosis, and cancer [9,30,31,32,33].”
From Picroside II as a Potential Anti-Inflammatory Agent (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746 · cited 1×
“jpg" NDATA ITEM> ]> Links between cancer and inflammation were first made in the nineteenth century, on the basis of observations that tumours often arose at sites of chronic inflammation and that inflammatory cells were present in biopsied samples from tumour”
Self-citationMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“TAMs and related cell types in mouse and human tumours generally have an M2 phenotype, which is oriented towards promoting tumour growth, remodelling tissues, promoting angiogenesis and suppressing adaptive immunity&hairsp”
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“This type of response might also contribute to successful chemotherapy or radiotherapy, according to recent data obtained by Lionel Apetoh and colleague”
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032 · cited 1×
“Cancer-related inflammation and adaptive immunity There is strong evidence from genetic studies of mouse models that cells of the adaptive immune system carry out surveillance and can eliminate nascent tumours (a process called immuno-editing”
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790 · cited 1×
“This transcription factor is constitutively activated both in tumour cells and in immune cells, and is involved in oncogenesis and inhibition of apoptosi”
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695 · cited 1×
“TAMs have been described as “obligate partners for tumour-cell migration, invasion and metastasis&rdquo”
Cited by
Items 901–1,000 of 1,085
Obesity and Inflammation: New Insights into Breast Cancer Development and Progression
Iyengar, N. M., Hudis, C. A., & Dannenberg, A. J. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.46 · Cited by 159
Zhang, C., Peng, L., Zhang, Y., Liu, Z., Li, W., Chen, S., & Li, G. (2017) · Medical Oncology · doi:10.1007/s12032-017-0963-9 · Cited by 165
Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?
Ward, M. P., E. Kane, L., A. Norris, L., Mohamed, B. M., Kelly, T., Bates, M., Clarke, A., Brady, N., Martin, C. M., Brooks, R. D., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01347-1 · Cited by 159
“In the early stages of tumorigenesis, NK cells can also detect and eliminate tumour cells [134], but patients where”
BackgroundIron induces anti-tumor activity in tumor-associated macrophages
Costa da Silva, M., Breckwoldt, M. O., Vinchi, F., Correia, M. P., Stojanovic, A., Thielmann, C. M., Meister, M., Muley, T., Warth, A., Platten, M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01479 · Cited by 164
Zhao, Q., Kuang, D.-M., Wu, Y., Xiao, X., Li, X.-F., Li, T.-J., & Zheng, L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100164 · Cited by 161
“Thus, a better understanding of the inflammatory context might provide a novel strategy for the rational design of anticancer therapies (45).”
BackgroundTomita, M., Shimizu, T. M., Ayabe, T., Yonei, A., & Onitsuka, T. (2011) · PubMed · Cited by 165
Liu, D., Song, L., Wei, J., Courtney, A. N., Gao, X., Marinova, E., Guo, L., Heczey, A., Asgharzadeh, S., Kim, E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59535 · Cited by 164
“Since TAMs provide a critical stromal support for tumor cell growth in NB and many other types of cancer (13–15), NKT cell–mediated killing or inhibition of TAMs explains how NKT cells may indirectly impede tumor growth.”
InfluentialFibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer
Zhang, H., Maric, I., DiPrima, M. J., Khan, J., Orentas, R. J., Kaplan, R. N., & Mackall, C. L. (2013) · Blood · doi:10.1182/blood-2012-08-449413 · Cited by 163
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V, De Souza, P., & Lee, C. K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.300 · Cited by 161
“…pathway (pre-existing inflammation) or the intrinsic pathway (oncogene activation) results in mobilisation of transcription factors and inflammatory mediators, giving rise to recruitment of inflammatory cells including neutrophils, and megakaryocytes causing thrombocytosis (Mantovani et al, 2008).”
BackgroundTargeting the DNA Damage Response in Cancer
Ljungman, M. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163
Development of a Prognostic Survival Algorithm for Patients with Metastatic Spine Disease
Paulino Pereira, N. R., Janssen, S. J., van Dijk, E., Harris, M. B., Hornicek, F. J., Ferrone, M. L., & Schwab, J. H. (2016) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.15.00975 · Cited by 163
Targeting cancer‐related inflammation in the era of immunotherapy
Nakamura, K., & Smyth, M. J. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2016.126 · Cited by 164
Cancer: An unknown territory; rethinking before going ahead
Upadhyay, A. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.09.002 · Cited by 184
“The direct involvement of the tissue microenvironment and inflammatory changes on the tumor growth survival is wellestablished.(3,4) However, a clear understanding of the underlying causes and factors is still elusive and requires more research.”
BackgroundTraditional Chinese Medicine and Immune Regulation
Ma, H.-D., Deng, Y.-R., Tian, Z., & Lian, Z.-X. (2013) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8332-0 · Cited by 163
Tumor Macroenvironment and Metabolism
Al-Zhoughbi, W., Huang, J., Paramasivan, G. S., Till, H., Pichler, M., Guertl-Lackner, B., & Hoefler, G. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.005 · Cited by 158
The Role of the Transcription Factor Nuclear Factor-kappa B in Thyroid Autoimmunity and Cancer
Giuliani, C., Bucci, I., & Napolitano, G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00471 · Cited by 158
“Activation of NF-κB in tumors can arise from both a response to classical inflammatory stimuli, such as infectious and physical or chemical agents (Figure 3A), and the result of oncogene activation (Figure 3B) (58).”
BackgroundLaird, B. J. A., Fallon, M., Hjermstad, M. J., Tuck, S., Kaasa, S., Klepstad, P., & McMillan, D. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7742 · Cited by 162
Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., & Kusmartsev, S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1209821 · Cited by 160
“Tumor-derived factors and local environmental conditions in the tumor vicinity regulate the function of tumorinfiltrated APCs and subsequently convert recruited, BM-derived myeloid cells into tumor-supporting cells such as immunosuppressive, proangiogenic TAMs, MDSCs, or regulatory/vasculogenic DCs [9, 10, 26, 35–40].”
BackgroundElusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors
Coffelt, S. B., Lewis, C. E., Naldini, L., Brown, J. M., Ferrara, N., & Palma, M. D. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090786 · Cited by 175
“These cells are released from the bone marrow as promonocytes, mature into monocytes in the circulation, infiltrate tumors, and differentiate further into tumor-associated macrophages (TAMs).(23,28) Once resident in tumors, macrophages express a wide array of proangiogenic factors, including vascular endothelial growt…”
BackgroundCaught in the cross fire: p53 in inflammation
Cooks, T., Harris, C. C., & Oren, M. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu134 · Cited by 162
“The shift from tumoricidal mediators like IL-12 and IFN-γ to cytokines like IL-8, IL-17, IL-23 and IL-13 allows the cancer cells to escape immune surveillance and utilize the system for their own good (65).”
BackgroundLi, Y., Jia, H., Yu, W., Xu, Y., Li, X., Li, Q., & Cai, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30071 · Cited by 159
Seth, K., Garg, S., Kumar, R., Purohit, P., Meena, V. S., Goyal, R., Banerjee, U. C., & Chakraborti, A. K. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400500e · Cited by 165
Servais, C., & Erez, N. (2013) · The Journal of Pathology · doi:10.1002/path.4103 · Cited by 152
Omega-3 supplements for patients in chemotherapy and/or radiotherapy: A systematic review
de Aguiar Pastore Silva, J., Emilia de Souza Fabre, M., & Waitzberg, D. L. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2014.11.005 · Cited by 158
“Probably to balance between cancer-promoting inflammatory responses and cancer-inhibiting inflammatory responses [36].”
BackgroundHe, H., Guo, C., Wang, J., Korzun, W. J., Wang, X.-Y., Ghosh, S., & Yang, H. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01892 · Cited by 158
Kuang, D.-M., Peng, C., Zhao, Q., Wu, Y., Zhu, L.-Y., Wang, J., Yin, X.-Y., Li, L., & Zheng, L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904094 · Cited by 157
“Emerging evidence indicates that the specific nature of inflammation and the tissue context may determine the ability of inflammatory response to facilitate or prevent tumor growth (32).”
BackgroundXie, D., Marks, R., Zhang, M., Jiang, G., Jatoi, A., Garces, Y. I., Mansfield, A., Molina, J., & Yang, P. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000585 · Cited by 163
“Inflammation is a known critical component of cancer progression.(5) Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in peripheral blood have been proposed as reliable indicators of the host’s inflammatory status; they have been identified as both prognostic and predictive biomarkers in man…”
BackgroundVilla, F. A., & Gerwick, L. G. (2010) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903296136 · Cited by 181
“a multitude of human diseases, including cancer, Alzheimer’s disease, and arthritis[3,4].”
BackgroundThe E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation
Ahmed, N., Zeng, M., Sinha, I., Polin, L., Wei, W.-Z., Rathinam, C., Flavell, R., Massoumi, R., & Venuprasad, K. (2011) · Nature Immunology · doi:10.1038/ni.2157 · Cited by 160
“Chronic infection and subsequent inflammation are critical environmental and epigenetic factors that contribute to tumor progressio”
BackgroundIntertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer
Herszényi, L., Hritz, I., Lakatos, G., Varga, M., & Tulassay, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131013240 · Cited by 158
“At least 20% of all cancers arise in association with chronic inflammation and infection [10,16–19].”
BackgroundInflammatory cytokines in human pancreatic cancer
Roshani, R., McCarthy, F. M., & Hagemann, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.014 · Cited by 173
Steinbrecher, K. A., Horowitz, N. A., Blevins, E. A., Barney, K. A., Shaw, M. A., Harmel-Laws, E., Finkelman, F. D., Flick, M. J., Pinkerton, M. D., Talmage, K. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3465 · Cited by 174
“Chronic inflammation is an established major risk factor in the development and progression of cancer (1).”
Szkandera, J., Gerger, A., Liegl-Atzwanger, B., Absenger, G., Stotz, M., Friesenbichler, J., Trajanoski, S., Stojakovic, T., Eberhard, K., Leithner, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28677 · Cited by 161
“metastasis.(5,6,34) Furthermore, TAMs contribute to tumor progression by secretion of factors that enhance neo-angiogenesis.”
BackgroundInfluentialHoshino, A., Ishii, G., Ito, T., Aoyagi, K., Ohtaki, Y., Nagai, K., Sasaki, H., & Ochiai, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3228 · Cited by 155
“It has been hypothesized that these stromal components are functionally organized to promote the survival of cancer cells in the host and to generate a favorable microenvironment for cancer cells in both primary and metastatic sites (3-7).”
BackgroundBöhm, S., Montfort, A., Pearce, O. M. T., Topping, J. H., Chakravarty, P., Everitt, G. L. A., Clear, A. J., McDermott, J. R., Ennis, D. P., Dowe, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2657 · Cited by 168
“Future work in larger cohorts may reveal insights into functionally different subsets of Treg cells with potentially different prognostic and predictive value (42, 43).”
BackgroundSelf-citationImpact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
Kim, S.-H., Roszik, J., Grimm, E. A., & Ekmekçioglu, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00067 · Cited by 169
“Tumor resistance to the immune response is assisted by the immunoediting of the immune signals induced by the tumors and their metabolites (2), possibly including that of checkpoint inhibitor upregulation, via inflammatory mechanisms mediated by arginine metabolism (5).”
BackgroundRole of diet and gut microbiota on colorectal cancer immunomodulation
Almeida, C. V. D., Camargo, M. R. D., Russo, E., & Amedei, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i2.151 · Cited by 151
The Role of Stroma in Tumor Development
Werb, Z., & Lu, P. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000127 · Cited by 176
“Monocytes are polarized to M1 macrophages by cytokines secreted from TH1 cells such as interferon γ, tumor necrosis factor α, and granulocyte-monocyte colony-stimulating factor; produce reactive oxygen and nitrogen intermediates and inflammatory cytokines; and are antitumor.(30,31) In contrast, monocytes exposed to cy…”
BackgroundAssociations between adipokines and obesity-related cancer
Paz-Filho, G., Lim, E. L., Wong, M.-L., & Licinio, J. (2010) · Frontiers in bioscience · doi:10.2741/3810 · Cited by 172
“to DNA damage (160) and angiogesis (161), and subsequently to the promotion of carcinogenesis and metastasis (162-164).”
BackgroundNovel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer
Shi, C., Yang, Y., Xia, Y., Okugawa, Y., Yang, J., Liang, Y., Chen, H., Zhang, P., Wang, F., Han, H., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308455 · Cited by 154
Park, S., Hatanpaa, K. J., Xie, Y., Mickey, B., Madden, C. J., Raisanen, J. M., Ramnarain, D. B., Xiao, G., Saha, D., Boothman, D. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4079 · Cited by 178
Sanchez-Lopez, E., Flashner-Abramson, E., Shalapour, S., Zhong, Z., Taniguchi, K., Levitzki, A., & Karin, M. (2016) · Oncogene · doi:10.1038/onc.2015.326 · Cited by 162
Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 157
“Oncogenic event also occurs due to mutations caused by reactive oxygen species and nitrogen intermediates (ROS and RNI) as well as superoxide and hydroxyl radicals produced as a result of inflammation [9].”
Patel, A., Sabbineni, H., Clarke, A., & Somanath, P. R. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.05.036 · Cited by 156
“Due to the barrier's disruption in cancer, inflammation remains as one of the seven hallmarks of cancer [112].”
BackgroundThe Role of B Cells and Humoral Immunity in Mycobacterium tuberculosis Infection
Kozakiewicz, L., Phuah, J. Y., Flynn, J. L., & Chan, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6111-1_12 · Cited by 174
“In mice, macrophages with the alternatively activated phenotype (M2) are conducive to persistence of certain pathogens [138] and contribute to the progression of tumor [139, 140].”
Chen, M.-F., Kuan, F.-C., Yen, T.-C., Lu, M.-S., Lin, P.-Y., Chung, Y.-H., Chen, W.-C., & Lee, K.-D. (2014) · Oncotarget · doi:10.18632/oncotarget.2368 · Cited by 155
Szkandera, J., Absenger, G., Liegl-Atzwanger, B., Pichler, M., Stotz, M., Samonigg, H., Glehr, M., Zacherl, M., Stojakovic, T., Gerger, A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.135 · Cited by 155
“Systemic www.bjcancer.com | DOI:10.1038/bjc.2013.135 1681 inflammation results in the secretion of inhibitory immunologic mediators, inducing immunosuppression due to impaired lymphocyte function (Mantovani et al, 2008).”
BackgroundInfluentialCochaud, S., Giustiniani, J., Thomas, C., Laprevotte, E., Garbar, C., Savoye, A.-M., Curé, H., Mascaux, C., Alberici, G., Bonnefoy, N., et al. (2013) · Scientific Reports · doi:10.1038/srep03456 · Cited by 156
“We believe that this speculation is a plausible scenario as we demonstrated here that ER(1) and ER(2) cell lines respond to IL-17A in a similar manner.”
Macrophages and cellular immunity in Drosophila melanogaster
Gold, K. S., & Brückner, K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.010 · Cited by 156
Chemokine Function in Periodontal Disease and Oral Cavity Cancer
Sahingur, S. E., & Yeudall, W. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00214 · Cited by 169
“Recent advances suggest that the tumor microenvironment plays an important role in the initiation and progression of malignant disease (78).”
BackgroundGlioma-initiating cells: A predominant role in microglia/macrophages tropism to glioma
Liang, Y., Xiao, H., Xu, M., Ye, X.-Z., Hu, J., Li, F., Li, M., Luo, C., Yu, S., Bian, X., et al. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.10.011 · Cited by 172
“Inflammatory mediators and inflammatory cells are indispensable components of the neoplastic microenvironment (Mantovani et al., 2008).”
BackgroundVerbeke, H., Karel, G., Damme, J. V., & Struyf, S. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.008 · Cited by 168
“Tumors are not just a collection of mutated cells growing uncontrolled, but also contain multiple other co-opted non-malignant cell types, including fibroblasts, endothelial cells forming blood and lymphatic vessels and immune cells [1,3].”
BackgroundDirican, A., Kucukzeybek, B. B., Alacacioglu, A., Kucukzeybek, Y., Erten, C., Varol, U., Somali, I., Demir, L., Bayoglu, I. V., Yildiz, Y., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0672-8 · Cited by 158
The role of natural polyphenols in cell signaling and cytoprotection against cancer development
Lewandowska, H., Kalinowska, M., Lewandowski, W., Stępkowski, T. M., & Brzóska, K. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.11.006 · Cited by 173
“Since the association between inflammation and cancer is strongly documented by epidemiological, clinical as well as biochemical andmolecular biology studies [170,171], the inhibition of inflammatory process by plant phenolic compounds should be regarded as important mechanism of their chemopreventive activity.”
BackgroundLolli, C., Basso, U., Derosa, L., Scarpi, E., Sava, T., Santoni, M., Crabb, S. J., Massari, F., Aieta, M., Conteduca, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10515 · Cited by 155
Yang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
“Studies suggest a strong correlation between colon cancer progression and tumor-associated inflammation [11, 89].”
BackgroundChang, Y. S., Jalgaonkar, S. P., Middleton, J. D., & Hai, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700455114 · Cited by 157
The multifaceted link between inflammation and human diseases
Rajendran, P., Chen, Y., Chen, Y., Chung, L., Tamilselvi, S., Shen, C., Day, C. H., Chen, R., Viswanadha, V. P., Kuo, W., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26479 · Cited by 148
“Relocation of inhibitory factors weaken p53-subordinate defensive reactions and, in this manner, cause the aggregation of oncogenic changes (Candido & Hagemann, 2013).”
BackgroundPolyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer
Mileo, A. M., Nisticò, P., & Miccadei, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00729 · Cited by 161
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 158
“Furthermore, cancer cells also promote systemic inflammation, which is induced by diverse immune cells, cytokines and acute phase proteins [119, 120].”
BackgroundRassouli, A., Saliba, J., Castano, R., Hier, M., & Zeitouni, A. G. (2015) · Head & Neck · doi:10.1002/hed.23567 · Cited by 160
“anti-inflammatory medications decrease incidence and reduce mortality from certain types of cancers.(5) Also,”
BackgroundInfluentialLiu, C., Lee, J.-J., Liu, T., Chang, Y., Hsu, Y., & Cheng, S. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23270 · Cited by 156
“Inflammation plays a critical role in many aspects of cancer, including tumor development, progression, clinical presentations, and prognosis [1].”
BackgroundNasser, M. W., Wani, N. A., Ahirwar, D. K., Powell, C. A., Ravi, J., Elbaz, M., Zhao, H., Padilla, L., Zhang, X., Shilo, K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2161 · Cited by 150
“org Cancer Res; 75(6) March 15, 2015 975”
BackgroundInfluentialPassardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8901 · Cited by 156
“It has increasingly been recognized that tumor infiltrating inflammatory cells are responsible for producing inflammatory mediators and cytokines that induce angiogenesis, tumor growth, invasion and metastasis [3-5].”
Belgiovine, C., Bello, E., Liguori, M., Craparotta, I., Mannarino, L., Paracchini, L., Beltrame, L., Marchini, S., Galmarini, C. M., Mantovani, A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.205 · Cited by 155
“…and the current evidence is that reciprocal interactions between cancer and stromal cells are of pivotal importance for the survival of tumour cells and disease progression (Knowles and Harris, 2007; Mantovani et al, 2008; Allavena and Mantovani, 2012; Coussens et al, 2013; Noy and Pollard, 2014).”
BackgroundSelf-citationRapin, N., Bagger, F. O., Jendholm, J., Mora-Jensen, H., Krogh, A., Kohlmann, A., Thiede, C., Borregaard, N., Bullinger, L., Winther, O., et al. (2014) · Blood · doi:10.1182/blood-2013-02-485771 · Cited by 159
Vetrano, S., Borroni, E. M., Sarukhan, A., Savino, B., Bonecchi, R., Correale, C., Arena, V., Fantini, M., Roncalli, M., Malesci, A., et al. (2010) · Gut · doi:10.1136/gut.2009.183772 · Cited by 153
Self-citationClifford, R., Zhang, J., Meerzaman, D. M., Lyu, M. S., Hu, Y., Cultraro, C. M., Finney, R. P., Kelley, J. M., Efroni, S., Greenblum, S. I., et al. (2010) · Hepatology · doi:10.1002/hep.23943 · Cited by 162
Templeton, A. J., Knox, J. J., Lin, X., Simantov, R., Xie, W., Lawrence, N. J., Broom, R. J., Fay, A. P., Rini, B. I., Donskov, F. N., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.033 · Cited by 155
“Smoldering inflammation in the tumor microenvironment has many tumor-promoting effects: it aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters response to antineoplastic agents [24].”
The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer
Doni, A., Stravalaci, M., Inforzato, A., Magrini, E. I., Mantovani, A., Garlanda, C., & Bottazzi, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00712 · Cited by 159
“Inflammation is a component of the tumor microenvironment promoting tumor development and growth (103).”
BackgroundSelf-citationThe IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer
Pastille, E., Wasmer, M.-H., Adamczyk, A., Vu, V. P., Mager, L. F., Phuong, N. N. T., Palmieri, V., Simillion, C., Hansen, W., Kasper, S., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0176-y · Cited by 150
Acquisition and maturation of oral microbiome throughout childhood: An update.
Sampaio‐Maia, B., & Monteiro-Silva, F. (2014) · PubMed · doi:10.4103/1735-3327.135876 · Cited by 155
Chan, K. E., Ong, E. Y. H., Chung, C. H., Ong, C. E. Y., Koh, B., Tan, D. J. H., Lim, W. H., Yong, J. N., Xiao, J., Wong, Z. Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.09.018 · Cited by 166
Giornale italiano di Dermatologia e Venereologia
Ribero, S., Quaglino, P., Sanlorenzo, M., Osella‐Abate, S., Marenco, F., Fierro, M. T., & Bernengo, M. G. (2012) · Institutional Research Information System University of Turin (University of Turin) · Cited by 155
Drexler, S. K., Bonsignore, L., Masin, M., Tardivel, A., Jackstadt, R., Hermeking, H., Schneider, P., Gross, O., Tschopp, J., & Yazdi, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209171109 · Cited by 151
“Recent studies have provided evidence that inflammation can drive tumor development (2), either through defined infectious agents (3), environmental factors (4), or an inflammatory microenvironment (5).”
BackgroundLaird, B. J., McMillan, D. C., Fayers, P., Fearon, K., Kaasa, S., Fallon, M. T., & Klepstad, P. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0120 · Cited by 149
The Microenvironment of Lung Cancer and Therapeutic Implications
Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 171
Protective links between vitamin D, inflammatory bowel disease and colon cancer
Meeker, S. M., Seamons, A., Maggio-Price, L., & Paik, J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.933 · Cited by 171
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
“, matrix metallo-proteinases [MMPs]] (3, 4).”
BackgroundKobatake, K., Ikeda, K., Nakata, Y., Yamasaki, N., Ueda, T., Kanai, A., Sentani, K., Sera, Y., Hayashi, T., Koizumi, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2230 · Cited by 175
“Inflammation plays a fundamental role in tumorigenesis (37, 38).”
BackgroundHashemi, M., Mirdamadi, M. S. A., Talebi, Y., Khaniabad, N., Banaei, G., Daneii, P., Gholami, S., Ghorbani, A., Tavakolpournegari, A., Farsani, Z. M., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106568 · Cited by 153
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
Ferdinande, L., Decaestecker, C., Verset, L., Mathieu, A., Moles Lopez, X., Negulescu, A.-M., Van Maerken, T., Salmon, I., Cuvelier, C. A., & Demetter, P. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.513 · Cited by 147
“Moreover, several inflammatory diseases increase the risk of developing cancer (Mantovani et al, 2008).”
BackgroundThe Association between Endometriosis and Chronic Endometritis
Takebayashi, A., Kimura, F., Kishi, Y., Ishida, M., Takahashi, A., Yamanaka, A., Takahashi, K., Suginami, H., & Murakami, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088354 · Cited by 154
“Furthermore, an inflammatory component is present in the microenvironment of most tumors that are not epidemiologically related to inflammation [33].”
BackgroundNdlovu, ′. N., Van Lint, C., Van Wesemael, K., Callebert, P., Chalbos, D., Haegeman, G., & Vanden Berghe, W. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01657-08 · Cited by 155
“Today, various links have been established between chronic inflammation and cancer, converging on the transcription factor NF- B (48, 53).”
BackgroundThe Yin-Yang of Tumor-Associated Neutrophils
Mantovani, A. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.014 · Cited by 149
“Inflammatory cells and mediators are a key component of the tumor microenvironment (Mantovani et al., 2008) and cancer-related inflammation has been proposed to represent the seventh hallmark of cancer.”
BackgroundSelf-citationReduced cell proliferation by IKK2 depletion in a mouse lung-cancer model
Xia, Y., Yeddula, N., Leblanc, M., Ke, E., Zhang, Y., Oldfield, E., Shaw, R. J., & Verma, I. M. (2012) · Nature Cell Biology · doi:10.1038/ncb2428 · Cited by 148
“Multiple NF-κB-regulated cytokines stimulate tumour-cell proliferation through autocrine and paracrine pathway”
BackgroundBuilding the niche: The role of the S100 proteins in metastatic growth
Lukanidin, E. M., & Sleeman, J. P. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.006 · Cited by 169
Bonifazi, M., Bravi, F., Gasparini, S., Vecchia, C. L., Gabrielli, A., Wells, A. U., & Renzoni, E. A. (2014) · CHEST Journal · doi:10.1378/chest.14-1475 · Cited by 163
Jin, G., Kawsar, H. I., Hirsch, S. A., Zeng, C., Jia, X., Feng, Z., Ghosh, S. K., Zheng, Q. Y., Zhou, A., McIntyre, T. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010993 · Cited by 164
“TAMs produce a wide array of tumor-promoting molecules, such as chemokines, cytokines, and growth factors, in the tumor microenvironment, to stimulate tumor cell proliferation, tumor angiogenesis, and metastasis [32].”
BackgroundNon-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Risk in a Large, Prospective Cohort
Ruder, E. H., Laiyemo, A. O., Graubard, B. I., Hollenbeck, A. R., Schatzkin, A. G., & Cross, A. J. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.38 · Cited by 154
“Intrinsic inflammation (via inflammatory cells and mediators within the tumor microenvironment), as well as extrinsic inflammation related to chronic inflammatory conditions, is a contributor to tumor progression (”
BackgroundSuh, B., Park, S., Shin, D. W., Yun, J. M., Keam, B., Yang, H.-K., Ahn, E., Lee, H., Park, J., & Cho, B.-K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu274 · Cited by 162
Nuclear Factor-κB and Tumor-Associated Macrophages
Mancino, A., & Lawrence, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1015 · Cited by 149
“TAM are recruited into tumors as monocytes from the bloodstream by chemotactic cytokines and growth factors such as: CCL2 (MCP-1), M-CSF (CSF-1), vascular endothelial growth factor (VEGF), angiopoietin-2, and CXCL12 (SDF1), released by both malignant and stromal tumor compartments (1, 3, 4).”
BackgroundLin, Y., Liu, Z., Qiu, Y., Zhang, J., Wu, H., Liang, R., Chen, G., Qin, G., Li, Y., & Zou, D. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.07.052 · Cited by 167
Xie, Q., Chen, P., Hu, W., Sun, P., He, W., Jiang, C., Kong, P., Liu, S., Chen, H., Yang, Y., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1638-9 · Cited by 168
Mirabella, F., Desiato, G., Mancinelli, S., Fossati, G., Rasile, M., Morini, R., Markicevic, M., Grimm, C., Amegandjin, C. A., Termanini, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.006 · Cited by 160
Microleakage of posterior packable resin composites with and without flowable liners.
Leevailoj, C., Cochran, M. A., Matis, B. A., Moore, B. K., & Platt, J. A. (2001) · PubMed · Cited by 193
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
Dey, A., Tergaonkar, V., & Lane, D. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2759 · Cited by 169
“Besides various other factors, tumour-associated macrophages, which are crucial for regulating tumour progression and angiogenesis, are also controlled by the NF-κB pathway (for more details refer to Ref”
BackgroundTransglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer
Mehta, K., Kumar, A., & Kim, H. I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.029 · Cited by 170
“Immune cells that infiltrate tumors can engage in cross-talk with cancer cells and modulate their growth, survival, and progression patterns [33,34].”
BackgroundZhang, Z., Schlamp, F., Huang, L., Clark, H., & Brayboy, L. (2020) · Reproduction · doi:10.1530/rep-19-0330 · Cited by 150
Metadata
- Authors
- Mantovani, A., Allavena, P., Sica, A., & Balkwill, F.
- Affiliations
- IRCCS Humanitas Research Hospital (IT)
- Fondazione Humanitas per la Ricerca (IT)
- Queen Mary University of London (GB)
- Venue
- Nature
- Published
- 2008-07-01
- Volume
- 454
- Issue
- 7203
- Pages
- 436-444
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2123105952
- Semantic Scholar
- b3a9e344a32ad6ca402d9149ac74b2b1df9e3076
- Cited by
- 11,399
- References
- 175
- Citations by year
- 2026: 419 · 2025: 554 · 2024: 655 · 2023: 761 · 2022: 848 · 2021: 878 · 2020: 864 · 2019: 759 · 2018: 752 · 2017: 732 · 2016: 692 · 2015: 683 · 2014: 643 · 2013: 574 · 2012: 510
- FWCI
- 26.32
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- tumor inflammation, tumor microenvironment, inflammatory mediators, angiogenesis, metastasis, immune evasion, chemoresistance, endocrine response, inflammatory signaling, therapeutic target
- MeSH terms
- Humans, Inflammation, Leukocytes, Neoplasm Invasiveness, Neoplasms, Oncogenes, Gonadal Steroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.